Cyclic nucleotide signalling in kidney fibrosis

International Journal of Molecular Sciences

Volumn 16, Issue 2, 2015, Pages 2320-2351

  Schinner, Elisabeth ^a   Wetzl, Veronika ^a   Schlossmann, Jens ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Cyclic adenosine monophosphate; Cyclic guanosine monophosphate; Cyclic nucleotides; Kidney fibrosis; Signalling

Indexed keywords

ADENYLATE CYCLASE; ATACIGUAT; ATRIAL NATRIURETIC FACTOR; AZATHIOPRINE; BELIMUMAB; CORTICOTROPIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; EPAC PROTEIN; GLUCOCORTICOID; GUANYLATE CYCLASE; HYDROXYCHLOROQUINE; KALLIKREIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; ORGANIC NITRATE; PEPTIDES AND PROTEINS; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PIRFENIDONE; RELAXIN; RIOCIGUAT; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG; GUANINE NUCLEOTIDE EXCHANGE FACTOR;

DIABETIC NEPHROPATHY; FOCAL GLOMERULOSCLEROSIS; GLOMERULOSCLEROSIS; HUMAN; HYPERTENSION; KIDNEY FIBROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; FIBROSIS; KIDNEY DISEASE; METABOLISM; PATHOLOGY;

ADENYLYL CYCLASES; ANIMALS; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC GMP; FIBROSIS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; KIDNEY DISEASES; NITRIC OXIDE; PHOSPHORIC DIESTER HYDROLASES; SIGNAL TRANSDUCTION;

EID: 84921866190     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16022320     Document Type: Review

References (184)

1. Eddy, A.A. The origin of scar-forming kidney myofibroblasts. Nat. Med. 2013, 19, 964-966.
2. Honda, E.; Park, A.-M.; Yoshida, K.; Tabuchi, M.; Munakata, H. Myofibroblasts: Biochemical and proteomic approaches to fibrosis. Tohoku J. Exp. Med. 2013, 230, 67-73.
3. LeBleu, V.S.; Taduri, G.; O’Connell, J.; Teng, Y.; Cooke, V.G.; Woda, C.; Sugimoto, H.; Kalluri, R. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 2013, 19, 1047-1053.
4. Mack, M.; Yanagita, M. Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int. 2014, doi:10.1038/ki.2014.287.
5. Lin, S.L.; Kisseleva, T.; Brenner, D.A.; Duffield, J.S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. 2008, 173, 1617-1627.
6. Campanholle, G.; Ligresti, G.; Gharib, S.A.; Duffield, J.S. Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis. Am. J. Physiol. Cell Physiol. 2013, 304, C591-C603.
7. Wakino, S.; Kanda, T.; Hayashi, K. Rho/Rho kinase as a potential target for the treatment of renal disease. Drug News Perspect. 2005, 18, 639-643.
8. Liu, Y. Cellular and molecular mechanisms of renal fibrosis. Nat. Rev. Nephrol. 2011, 7, 684-696.
9. Vernon, M.A.; Mylonas, K.J.; Hughes, J. Macrophages and renal fibrosis. Semin. Nephrol. 2010, 30, 302-317.
10. Matavelli, L.C.; Siragy, H.M. Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. J. Cardiovasc. Pharmacol. 2013, 61, 17-22.
11. Kimura, K.; Iwano, M.; Higgins, D.F.; Yamaguchi, Y.; Nakatani, K.; Harada, K.; Kubo, A.; Akai, Y.; Rankin, E.B.; Neilson, E.G.; et al. Stable expression of HIF-1α in tubular epithelial cells promotes interstitial fibrosis. Am. J. Physiol. Renal Physiol. 2008, 295, F1023-F1029.
12. Higgins, G.C.; Coughlan, M.T. Mitochondrial dysfunction and mitophagy: The beginning and end to diabetic nephropathy? Br. J. Pharmacol. 2014, 171, 1917-1942.
13. Lee, D.Y.; Wauquier, F.; Eid, A.A.; Roman, L.J.; Ghosh-Choudhury, G.; Khazim, K.; Block, K.; Gorin, Y. Nox4 NADPH oxidase mediates peroxynitrite-dependent uncoupling of endothelial nitric-oxide synthase and fibronectin expression in response to angiotensin II: Role of mitochondrial reactive oxygen species. J. Biol. Chem. 2013, 288, 28668-28686.
14. Rosenbloom, J.; Mendoza, F.A.; Jimenez, S.A. Strategies for anti-fibrotic therapies. Biochim. Biophys. Acta 2013, 1832, 1088-1103.
15. Chen, J.F.; Liu, H.; Ni, H.F.; Lv, L.L.; Zhang, M.H.; Zhang, A.H.; Tang, R.N.; Chen, P.S.; Liu, B.C. Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5/6 nephrectomized rats. PLoS One 2013, 8, e83593.
16. RamachandraRao, S.P.; Zhu, Y.; Ravasi, T.; McGowan, T.A.; Toh, I.; Dunn, S.R.; Okada, S.; Shaw, M.A.; Sharma, K. Pirfenidone is renoprotective in diabetic kidney disease. J. Am. Soc. Nephrol. 2009, 20, 1765-1775.
17. Wang, Y.; Krämer, S.; Loof, T.; Martini, S.; Kron, S.; Kawachi, H.; Shimizu, F.; Neumayer, H.; Peters, H. Enhancing cGMP in experimental progressive renal fibrosis: Soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. Am. J. Physiol. Renal Physiol. 2006, 290, F167-F176.
18. Betz, B.; Conway, B.R. Recent advances in animal models of diabetic nephropathy. Nephron. Exp Nephrol. 2014, 126, 191-195.
19. Hodgin, J.B.; Nair, V.; Zhang, H.; Randolph, A.; Harris, R.C.; Nelson, R.G.; Weil, E.J.; Cavalcoli, J.D.; Patel, J.M.; Brosius, F.C.,; et al. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes 2013, 62, 299-308.
20. Brosius, F.C., New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev. Endocr. Metab. Disord. 2008, 9, 245-254.
21. Roscioni, S.S.; Heerspink, H.J.; de Zeeuw, D. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat. Rev. Nephrol. 2014, 10, 77-87.
22. Komers, R.; Oyama, T.T.; Beard, D.R.; Tikellis, C.; Xu, B.; Lotspeich, D.F.; Anderson, S. Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. Kidney Int. 2011, 79, 432-442.
23. Ott, I.M.; Alter, M.L.; von Websky, K.; Kretschmer, A.; Tsuprykov, O.; Sharkovska, Y.; Krause-Relle, K.; Raila, J.; Henze, A.; Stasch, J.P.; et al. Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade. PLoS One 2012, 7, e42623.
24. Braun, N.; Schweisfurth, A.; Lohofener, C.; Lange, C.; Grundemann, C.; Kundt, G.; Grone, H.J. Epidemiology of glomerulonephritis in Northern Germany. Int. Urol. Nephrol. 2011, 43, 1117-1126.
25. Appel, G.B.; Appel, A.S. New diagnostic tests and new therapies for glomerular diseases. Blood Purif. 2013, 35, 81-85.
26. Ponticelli, C.; Graziani, G. Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults. Expert. Rev. Clin. Immunol. 2013, 9, 251-261.
27. Shankland, S.J.; Pollak, M.R. A suPAR circulating factor causes kidney disease. Nat. Med. 2011, 17, 926-927.
28. Wei, C.; El Hindi, S.; Li, J.; Fornoni, A.; Goes, N.; Sageshima, J.; Maiguel, D.; Karumanchi, S.A.; Yap, H.K.; Saleem, M.; et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 2011, 17, 952-960.
29. Hogan, J.; Bomback, A.S.; Mehta, K.; Canetta, P.A.; Rao, M.K.; Appel, G.B.; Radhakrishnan, J.; Lafayette, R.A. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin. J. Am. Soc. Nephrol. 2013, 8, 2072-2081.
30. Kronbichler, A.; Kerschbaum, J.; Fernandez-Fresnedo, G.; Hoxha, E.; Kurschat, C.E.; Busch, M.; Bruchfeld, A.; Mayer, G.; Rudnicki, M. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: A systematic review. Am. J. Nephrol. 2014, 39, 322-330.
31. Sharma, R.; Ix, J.H.; Mathew, A.V.; Cho, M.; Pflueger, A.; Dunn, S.R.; Francos, B.; Sharma, S.; Falkner, B.; McGowan, T.A.; et al. Cyclosporine protects glomeruli from FSGS factor via an increase in glomerular cAMP. Transplantation 1996, 62, 1916-1920.
32. Balow, J.E.; Austin, H.A., Renal disease in systemic lupus erythematosus. Rheum. Dis. Clin. N. Am. 1988, 14, 117-133.
33. Michaelson, J.S.; Wisniacki, N.; Burkly, L.C.; Putterman, C. Role of TWEAK in lupus nephritis: A bench-to-bedside review. J. Autoimmun. 2012, 39, 130-142.
34. Crampton, S.P.; Morawski, P.A.; Bolland, S. Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus. Dis. Model. Mech. 2014, 7, 1033-1046.
35. Liu, D.; Ahmet, A.; Ward, L.; Krishnamoorthy, P.; Mandelcorn, E.D.; Leigh, R.; Brown, J.P.; Cohen, A.; Kim, H. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma. Clin. Immunol. 2013, 9, 30.
36. Runkel, L.; Stacey, J. Lupus clinical development: Will belimumab’s approval catalyse a new paradigm for SLE drug development? Expert Opin. Biol. Ther. 2014, 14, 491-501.
37. Donadio, J.V., Jr.; Glassock, R.J. Immunosuppressive drug therapy in lupus nephritis. Am. J. Kidney Dis. 1993, 21, 239-250.
38. Fox, R.I. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin. Arthritis. Rheum. 1993, 23, 82-91.
39. Zheng, S.; Huang, Y.; Yang, L.; Chen, T.; Xu, J.; Epstein, P.N. Uninephrectomy of diabetic OVE26 mice greatly accelerates albuminuria, fibrosis, inflammatory cell infiltration and changes in gene expression. Nephron. Exp. Nephrol. 2011, 119, e21-e32.
40. Conway, B.R.; Rennie, J.; Bailey, M.A.; Dunbar, D.R.; Manning, J.R.; Bellamy, C.O.; Hughes, J.; Mullins, J.J. Hyperglycemia and renin-dependent hypertension synergize to model diabetic nephropathy. J. Am. Soc. Nephrol. 2012, 23, 405-411.
41. Eddy, A.A.; Lopez-Guisa, J.M.; Okamura, D.M.; Yamaguchi, I. Investigating mechanisms of chronic kidney disease in mouse models. Pediatr. Nephrol. 2012, 27, 1233-1247.
42. Bonventre, J.V.; Yang, L. Cellular pathophysiology of ischemic acute kidney injury. J. Clin. Investig. 2011, 121, 4210-4221.
43. Komers, R. Rho kinase inhibition in diabetic kidney disease. Br. J. Clin. Pharmacol. 2013, 76, 551-559.
44. Wakeland, E.K.; Liu, K.; Graham, R.R.; Behrens, T.W. Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001, 15, 397-408.
45. Fox, R.I.; Kang, H.I. Mechanism of action of antimalarial drugs: Inhibition of antigen processing and presentation. Lupus 1993, 2, S9-S12.
46. Schmidt, H.H.; Schmidt, P.M.; Stasch, J.P. NO- and haem-independent soluble guanylate cyclase activators. Handb. Exp. Pharmacol. 2009, 191, 309-339.
47. Defer, N.; Best-Belpomme, M.; Hanoune, J. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am. J. Physiol. Renal Physiol. 2000, 279, F400-F416.
48. Swaney, J.S.; Roth, D.M.; Olson, E.R.; Naugle, J.E.; Meszaros, J.G.; Insel, P.A. Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase. Proc. Natl. Acad. Sci. USA 2005, 102, 437-442.
49. Dunkern, T.R.; Torsten, R.; Feurstein, D.; Rossi, G.A.; Sabatini, F.; Hatzelmann, A. Inhibition of TGFβ induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur. J. Pharmacol. 2007, 572, 12-22.
50. Vatner, S.F.; Yan, L.; Ishikawa, Y.; Vatner, D.E.; Sadoshima, J. Adenylyl cyclase type 5 disruption prolongs longevity and protects the heart against stress. Circ. J. 2009, 73, 195-200.
51. Kavitha, C.; Rajamani, K.; Vadivel, E. Coleus forskohlii—A comprehensive review on morphology, phytochemistry and pharmacological aspects. J. Med. Plants Res. 2010, 4, 278-285.
52. Dubey, R.K.; Rosselli, M.; Gillespie, D.G.; Mi, Z.; Jackson, E.K. Extracellular 3',5'-cAMP-adenosine pathway inhibits glomerular mesangial cell growth. J. Pharmacol. Exp. Ther. 2010, 333, 808-815.
53. Yu, Z.; Kong, Q.; Kone, B.C. CREB trans-activation of disruptor of telomeric silencing-1 mediates forskolin inhibition of CTGF transcription in mesangial cells. Am. J. Physiol. Renal Physiol. 2010, 298, F617-F624.
54. Kwak, H.J.; Park, K.M.; Choi, H.E.; Chung, K.S.; Lim, H.J.; Park, H.Y. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways. Cell Signal. 2008, 20, 803-814.
55. Francis, S.H.; Turko, I.V.; Corbin, J.D. Cyclic nucleotide phosphodiesterases: Relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 2001, 65, 1-52.
56. Sonnenburg, W.K.; Seger, D.; Beavo, J.A. Molecular cloning of a cDNA encoding the “61 kDa” calmodulin-stimulated cyclic nucleotide phosphodiesterase. Tissue-specific expression of structurally related isoforms. J. Biol. Chem. 1993, 268, 645-652.
57. Snyder, P.B.; Florio, V.A.; Ferguson, K.; Loughney, K. Isolation, expression and analysis of splice variants of a human Ca2+/calmodulin-stimulated phosphodiesterase (PDE1A). Cell Signal. 1999, 11, 535-544.
58. Miller, C.L.; Cai, Y.; Oikawa, M.; Thomas, T.; Dostmann, W.R.; Zaccolo, M.; Fujiwara, K.; Yan, C. Cyclic nucleotide phosphodiesterase 1A: A key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart. Basic Res. Cardiol. 2011, 106, 1023-1039.
59. Dousa, T.P. Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int. 1999, 55, 29-62.
60. Souness, J.E.; Aldous, D.; Sargent, C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 2000, 47, 127-162.
61. Chini, C.C.; Grande, J.P.; Chini, E.N.; Dousa, T.P. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. Regulation of superoxidation and mitogenesis. J. Biol. Chem. 1997, 272, 9854-9859.
62. Kohyama, T.; Liu, X.; Wen, F.Q.; Zhu, Y.K.; Wang, H.; Kim, H.J.; Takizawa, H.; Cieslinski, L.B.; Barnette, M.S.; Rennard, S.I. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am. J. Respir. Cell Mol. Biol. 2002, 26, 694-701.
63. Kohyama, T.; Liu, X.; Zhu, Y.K.; Wen, F.Q.; Wang, H.J.; Fang, Q.; Kobayashi, T.; Rennard, S.I. Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-α and neutrophil elastase. Am. J. Respir. Cell Mol. Biol. 2002, 27, 487-494.
64. Togo, S.; Liu, X.; Wang, X.; Sugiura, H.; Kamio, K.; Kawasaki, S.; Kobayashi, T.; Ertl, R.F.; Ahn, Y.; Holz, O.; et al. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGFβ1-stimulated fibroblasts. Am. J. Physiol. Lung Cell Mol. Physiol. 2009, 296, L959-L969.
65. Tsuboi, Y.; Shankland, S.J.; Grande, J.P.; Walker, H.J.; Johnson, R.J.; Dousa, T.P. Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. J. Clin. Investig. 1996, 98, 262-270.
66. Tam, F.W.; Smith, J.; Agarwal, S.; Karkar, A.M.; Morel, D.; Thompson, E.M.; Pusey, C.D. Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis. Nephron 2000, 84, 58-66.
67. Tikoo, K.; Lodea, S.; Karpe, P.A.; Kumar, S. Calorie restriction mimicking effects of roflumilast prevents diabetic nephropathy. Biochem. Biophys. Res. Commun. 2014, 450, 1581-1586.
68. Calverley, P.M.; Rabe, K.F.; Goehring, U.M.; Kristiansen, S.; Fabbri, L.M.; Martinez, F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials. Lancet 2009, 374, 685-694.
69. Sadakane, C.; Kase, Y.; Koseki, J.; Hasegawa, Y.; Shindo, S.; Maruyama, H.; Takeda, S.; Takeda, H.; Hattori, T. Effects of TJN-598, a new selective phosphodiesterase type IV inhibitor on anti-Thy1 nephritis in rats. Clin. Exp. Nephrol. 2011, 15, 14-24.
70. Keravis, T.; Monneaux, F.; Yougbare, I.; Gazi, L.; Bourguignon, J.J.; Muller, S.; Lugnier, C. Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. PLoS One 2012, 7, e28899.
71. Lu, D.; Aroonsakool, N.; Yokoyama, U.; Patel, H.H.; Insel, P.A. Increase in cellular cyclic AMP concentrations reverses the profibrogenic phenotype of cardiac myofibroblasts: A novel therapeutic approach for cardiac fibrosis. Mol. Pharmacol. 2013, 84, 787-793.
72. Lakics, V.; Karran, E.H.; Boess, F.G. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010, 59, 367-374.
73. Ward, A.; Clissold, S.P. Pentoxifylline—A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987, 34, 50-97.
74. Chen, Y.M.; Chien, C.T.; Hu-Tsai, M.I.; Wu, K.D.; Tsai, C.C.; Wu, M.S.; Tsai, T.J. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int. 1999, 56, 932-943.
75. Lin, S.L.; Chen, Y.M.; Chien, C.T.; Chiang, W.C.; Tsai, C.C.; Tsai, T.J. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J. Am. Soc. Nephrol. 2002, 13, 2916-2929.
76. Lin, S.L.; Chen, R.H.; Chen, Y.M.; Chiang, W.C.; Lai, C.F.; Wu, K.D.; Tsai, T.J. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J. Am. Soc. Nephrol. 2005, 16, 2702-2713.
77. Shirazi, M.; Noorafshan, A.; Farrokhi, A. Effects of pentoxifylline on renal structure after urethral obstruction in rat: A stereological study. Cent. Eur. J. Urol. 2011, 64, 30-33.
78. Yagmurlu, A.; Boleken, M.E.; Ertoy, D.; Ozsan, M.; Gokcora, I.H.; Dindar, H. Preventive effect of pentoxifylline on renal scarring in rat model of pyelonephritis. Urology 2003, 61, 1037-1041.
79. He, T.; Cooper, M.E. Diabetic nephropathy: Renoprotective effects of pentoxifylline in the PREDIAN trial. Nat. Rev. Nephrol. 2014, 10, 547-548.
80. Schiller, M.; Verrecchia, F.; Mauviel, A. Cyclic adenosine 3',5'-monophosphate-elevating agents inhibit transforming growth factor-β-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism. Oncogene 2003, 22, 8881-8890.
81. Mehra, A.; Wrana, J.L. TGFβ and the Smad signal transduction pathway. Biochem. Cell Biol. 2002, 80, 605-622.
82. Shi, Y.; Massague, J. Mechanisms of TGFβ signaling from cell membrane to the nucleus. Cell 2003, 113, 685-700.
83. De Rooij, J.; Zwartkruis, F.J.T.; Verheijen, M.H.G.; Cool, R.H.; Nijman, S.M.B.; Wittinghofer, A.; Bos, J.L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998, 396, 474-477.
84. Okumura, S.; Fujita, T.; Cai, W.; Jin, M.; Namekata, I.; Mototani, Y.; Jin, H.; Ohnuki, Y.; Tsuneoka, Y.; Kurotani, R.; et al. Epac1-dependent phospholamban phosphorylation mediates the cardiac response to stresses. J. Clin. Investig. 2014, 124, 2785-2801.
85. Yokoyama, U.; Minamisawa, S.; Quan, H.; Akaike, T.; Suzuki, S.; Jin, M.; Jiao, Q.; Watanabe, M.; Otsu, K.; Iwasaki, S.; et al. Prostaglandin E2-activated Epac promotes neointimal formation of the rat ductus arteriosus by a process distinct from that of cAMP-dependent protein kinase A. J. Biol. Chem. 2008, 283, 28702-28709.
86. Insel, P.A.; Murray, F.; Yokoyama, U.; Romano, S.; Yun, H.; Brown, L.; Snead, A.; Lu, D.; Aroonsakool, N. cAMP and Epac in the regulation of tissue fibrosis. Br. J. Pharmacol. 2012, 166, 447-456.
87. Stokman, G.; Qin, Y.; Booij, T.H.; Ramaiahgari, S.; Lacombe, M.; Dolman, M.E.; van Dorenmalen, K.M.; Teske, G.J.; Florquin, S.; Schwede, F.; et al. Epac-Rap signaling reduces oxidative stress in the tubular epithelium. J. Am. Soc. Nephrol. 2014, 25, 1474-1485.
88. Dendooven, A.; Ishola, D.A., Jr.; Nguyen, T.Q.; van der Giezen, D.M.; Kok, R.J.; Goldschmeding, R.; Joles, J.A. Oxidative stress in obstructive nephropathy. Int. J. Exp. Pathol. 2011, 92, 202-210.
89. Nagae, T.; Mori, K.; Mukoyama, M.; Kasahara, M.; Yokoi, H.; Suganami, T.; Sawai, K.; Yoshioka, T.; Koshikawa, M.; Saito, Y.; et al. Adrenomedullin inhibits connective tissue growth factor expression, extracellular signal-regulated kinase activation and renal fibrosis. Kidney Int. 2008, 74, 70-80.
90. Chao, J.; Kato, K.; Zhang, J.J.; Dobrzynski, E.; Wang, C.; Agata, J.; Chao, L. Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury. Peptides 2001, 22, 1731-1737.
91. Zhang, J.J.; Yoshida, H.; Chao, L.; Chao, J. Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats. Hum. Gene Ther. 2000, 11, 1817-1827.
92. Schlossmann, J.; Schinner, E. cGMP becomes a drug target. Naunyn Schmiedebergs Arch. Pharmacol. 2012, 385, 243-252.
93. Peters, H.; Border, W.A.; Noble, N.A. Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. Kidney Int. 2000, 57, 992-1001.
94. Peters, H.; Daig, U.; Martini, S.; Ruckert, M.; Schaper, F.; Liefeldt, L.; Kramer, S.; Neumayer, H.H. NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. Kidney Int. 2003, 64, 509-518.
95. Yamaleyeva, L.M.; Lindsey, S.H.; Varagic, J.; Zhang, L.L.; Gallagher, P.E.; Chen, A.F.; Chappell, M.C. Amelioration of renal injury and oxidative stress by the nNOS inhibitor L-VNIO in the salt-sensitive mRen2.Lewis congenic rat. J. Cardiovasc. Pharmacol. 2012, 59, 529-538.
96. Ezzidi, I.; Mtiraoui, N.; Mohamed, M.B.; Mahjoub, T.; Kacem, M.; Almawi, W.Y. Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and −786T>C gene variants with diabetic nephropathy. J. Diabetes Complicat. 2008, 22, 331-338.
97. Gheorghiade, M.; Marti, C.N.; Sabbah, H.N.; Roessig, L.; Greene, S.J.; Bohm, M.; Burnett, J.C.; Campia, U.; Cleland, J.G.; Collins, S.P.; et al. Soluble guanylate cyclase: A potential therapeutic target for heart failure. Heart Fail. Rev. 2013, 18, 123-134.
98. Vaziri, N.D.; Ni, Z.; Oveisi, F.; Liang, K.; Pandian, R. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002, 39, 135-141.
99. Liu, C.P.; Kuo, M.S.; Wu, B.N.; Chai, C.Y.; Huang, H.T.; Chung, P.W.; Chen, I.J. NO-releasing xanthine KMUP-1 bonded by simvastatin attenuates bleomycin-induced lung inflammation and delayed fibrosis. Pulm Pharmacol. Ther. 2014, 27, 17-28.
100. Knorr, A.; Hirth-Dietrich, C.; Alonso-Alija, C.; Harter, M.; Hahn, M.; Keim, Y.; Wunder, F.; Stasch, J.P. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung 2008, 58, 71-80.
101. Kashiwagi, M.; Shinozaki, M.; Hirakata, H.; Tamaki, K.; Hirano, T.; Tokumoto, M.; Goto, H.; Okuda, S.; Fujishima, M. Locally activated renin-angiotensin system associated with TGFβ1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J. Am. Soc. Nephrol. 2000, 11, 616-624.
102. Forbes, M.S.; Thornhill, B.A.; Park, M.H.; Chevalier, R.L. Lack of endothelial nitric-oxide synthase leads to progressive focal renal injury. Am. J. Pathol. 2007, 170, 87-99.
103. Szabo, C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol. Lett. 2003, 140, 105-112.
104. Jeong, K.H.; Lee, T.W.; Ihm, C.G.; Lee, S.H.; Moon, J.Y.; Lim, S.J. Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. Am. J. Nephrol. 2009, 29, 274-282.
105. Masuyama, H.; Tsuruda, T.; Kato, J.; Imamura, T.; Asada, Y.; Stasch, J.P.; Kitamura, K.; Eto, T. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens. Res. 2009, 32, 597-603
106. Keil, A.; Blom, I.E.; Goldschmeding, R.; Rupprecht, H.D. Nitric oxide down-regulates connective tissue growth factor in rat mesangial cells. Kidney Int. 2002, 62, 401-411.
107. Schmidt, H.H.; Hofmann, F.; Stasch, J.P. Handbook of Experimental Pharmacology 191. cGMP: Generators, effectors and therapeutic implications. Pref. Handb. Exp. Pharmacol. 2009, 191, v-vi.
108. Nossaman, B.; Pankey, E.; Kadowitz, P. Stimulators and activators of soluble guanylate cyclase: Review and potential therapeutic indications. Crit. Care Res. Pract. 2012, 2012, 290805.
109. Deruelle, P.; Balasubramaniam, V.; Kunig, A.M.; Seedorf, G.J.; Markham, N.E.; Abman, S.H. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Neonatology 2006, 90, 135-144.
110. Dumitrascu, R.; Weissmann, N.; Ghofrani, H.A.; Dony, E.; Beuerlein, K.; Schmidt, H.; Stasch, J.P.; Gnoth, M.J.; Seeger, W.; Grimminger, F.; et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006, 113, 286-295.
111. Masuyama, H.; Tsuruda, T.; Kato, J.; Imamura, T.; Asada, Y.; Stasch, J.P.; Kitamura, K.; Eto, T. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension 2006, 48, 972-978.
112. Beyer, C.; Zenzmaier, C.; Palumbo-Zerr, K.; Mancuso, R.; Distler, A.; Dees, C.; Zerr, P.; Huang, J.; Maier, C.; Pachowsky, M.L.; et al. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling. Ann. Rheum. Dis. 2014, doi:10.1136/annrheumdis-2013-204508.
113. Friebe, A.; Mullershausen, F.; Smolenski, A.; Walter, U.; Schultz, G.; Koesling, D. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol. Pharmacol. 1998, 54, 962-967.
114. Hwang, T.L.; Wu, C.C.; Guh, J.H.; Teng, C.M. Potentiation of tumor necrosis factor-α expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway. Biochem. Pharmacol. 2003, 66, 149-156.
115. Feelisch, M.; Kotsonis, P.; Siebe, J.; Clement, B.; Schmidt, H.H. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Mol. Pharmacol. 1999, 56, 243-253.
116. Ko, F.N.; Wu, C.C.; Kuo, S.C.; Lee, F.Y.; Teng, C.M. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994, 84, 4226-4233.
117. Wu, C.C.; Ko, F.N.; Kuo, S.C.; Lee, F.Y.; Teng, C.M. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. 1995, 116, 1973-1978.
118. Huh, J.W.; Kim, S.Y.; Lee, J.H.; Lee, Y.S. YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice. Pulm Pharmacol. Ther. 2011, 24, 638-646.
119. Schinner, E.; Schramm, A.; Kees, F.; Hofmann, F.; Schlossmann, J. The cyclic GMP-dependent protein kinase Iα suppresses kidney fibrosis. Kidney Int. 2013, 84, 1198-1206.
120. Wang, Y.; Kramer, S.; Loof, T.; Martini, S.; Kron, S.; Kawachi, H.; Shimizu, F.; Neumayer, H.H.; Peters, H. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. Kidney Int. 2005, 68, 47-61.
121. Hohenstein, B.; Daniel, C.; Wagner, A.; Stasch, J.P.; Hugo, C. Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis. Am. J. Physiol Renal Physiol. 2005, 288, F685-F693.
122. Stasch, J.P; Dembowsky, K.; Perzborn, E.; Stahl, E.; Schramm, M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: In vivo studies. Br. J. Pharmacol. 2002, 135, 344-355.
123. Wang-Rosenke, Y.; Mika, A.; Khadzhynov, D.; Loof, T.; Neumayer, H.H.; Peters, H. Stimulation of soluble guanylate cyclase improves renal recovery after relief of unilateral ureteral obstruction. J. Urol. 2011, 186, 1142-1149.
124. Stasch, J.P.; Hobbs, A.J. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb. Exp. Pharmacol. 2009, 191, 277-308.
125. Conole, D.; Scott, L.J. Riociguat: First global approval. Drugs 2013, 73, 1967-1975.
126. Geschka, S.; Kretschmer, A.; Sharkovska, Y.; Evgenov, O.V.; Lawrenz, B.; Hucke, A.; Hocher, B.; Stasch, J.P. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One 2011, 6, e21853.
127. Sharkovska, Y.; Kalk, P.; Lawrenz, B.; Godes, M.; Hoffmann, L.S.; Wellkisch, K.; Geschka, S.; Relle, K.; Hocher, B.; Stasch, J.P. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J. Hypertens. 2010, 28, 1666-1675.
128. Kalk, P.; Godes, M.; Relle, K.; Rothkegel, C.; Hucke, A.; Stasch, J.P.; Hocher, B. NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br. J. Pharmacol. 2006, 148, 853-859.
129. Benz, K.; Orth, S.R.; Simonaviciene, A.; Linz, W.; Schindler, U.; Rutten, H.; Amann, K. Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage. Kidney Blood Press Res. 2007, 30, 224-233.
130. Erdmann, E.; Semigran, M.J.; Nieminen, M.S.; Gheorghiade, M.; Agrawal, R.; Mitrovic, V.; Mebazaa, A. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur. Heart J. 2013, 34, 57-67.
131. Yougbare, I.; Keravis, T.; Abusnina, A.; Decossas, M.; Schall, N.; Muller, S.; Lugnier, C. Cyclic GMP catabolism up-regulation in MRL/lpr lupus-prone mice is associated with organ remodeling. Biochim. Biophys. Acta 2014, 1842, 916-926.
132. Cui, W.; Maimaitiyiming, H.; Qi, X.; Norman, H.; Zhou, Q.; Wang, X.; Fu, J.; Wang, S. Increasing cGMP-dependent protein kinase activity attenuates unilateral ureteral obstruction-induced renal fibrosis. Am. J. Physiol. Renal Physiol. 2014, 306, F996-F1007.
133. Rodriguez-Iturbe, B.; Ferrebuz, A.; Vanegas, V.; Quiroz, Y.; Espinoza, F.; Pons, H.; Vaziri, N.D. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int. 2005, 68, 2131-2142.
134. Tapia, E.; Sanchez-Lozada, L.G.; Soto, V.; Manrique, A.M.; Ortiz-Vega, K.M.; Santamaria, J.; Medina-Campos, O.N.; Cristobal, M.; Avila-Casado, C.; Pedraza-Chaverri, J.; et al. Sildenafil treatment prevents glomerular hypertension and hyperfiltration in rats with renal ablation. Kidney Blood Press Res. 2012, 35, 273-280.
135. Bae, E.H.; Kim, I.J.; Joo, S.Y.; Kim, E.Y.; Kim, C.S.; Choi, J.S.; Ma, S.K.; Kim, S.H.; Lee, J.U.; Kim, S.W. Renoprotective effects of sildenafil in DOCA-salt hypertensive rats. Kidney Blood Press Res. 2012, 36, 248-257.
136. Muzaffar, S.; Shukla, N.; Srivastava, A.; Angelini, G.D.; Jeremy, J.Y. Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells. Br. J. Pharmacol. 2005, 146, 109-117.
137. Guzeloglu, M.; Yalcinkaya, F.; Atmaca, S.; Bagriyanik, A.; Oktar, S.; Yuksel, O.; Fansa, I.; Hazan, E. The beneficial effects of tadalafil on renal ischemia-reperfusion injury in rats. Urol. Int. 2011, 86, 197-203.
138. Sohotnik, R.; Nativ, O.; Abbasi, A.; Awad, H.; Frajewicki, V.; Bishara, B.; Sukhotnik, I.; Armaly, Z.; Aronson, D.; Heyman, S.N.; et al. Phosphodiesterase-5 inhibition attenuates early renal ischemia-reperfusion-induced acute kidney injury: Assessment by quantitative measurement of urinary NGAL and KIM-1. Am. J. Physiol. Renal Physiol. 2013, 304, F1099-F1104.
139. Hsu, S.Y.; Nakabayashi, K.; Nishi, S.; Kumagai, J.; Kudo, M.; Sherwood, O.D.; Hsueh, A.J. Activation of orphan receptors by the hormone relaxin. Science 2002, 295, 671-674.
140. Bathgate, R.A.; Halls, M.L.; van der Westhuizen, E.T.; Callander, G.E.; Kocan, M.; Summers, R.J. International Union of Pharmacology LVII: Recommendations for the nomenclature of receptors for relaxin family peptides. Pharmacol. Rev. 2006, 58, 7-31.
141. Bennett, R.G. Relaxin and its role in the development and treatment of fibrosis. Transl. Res. 2009, 154, 1-6.
142. Heeg, M.H.; Koziolek, M.J.; Vasko, R.; Schaefer, L.; Sharma, K.; Muller, G.A.; Strutz, F. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int. 2005, 68, 96-109.
143. Mookerjee, I.; Hewitson, T.D.; Halls, M.L.; Summers, R.J.; Mathai, M.L.; Bathgate, R.A.; Tregear, G.W.; Samuel, C.S. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J. 2009, 23, 1219-1229.
144. Masterson, R.; Hewitson, T.D.; Kelynack, K.; Martic, M.; Parry, L.; Bathgate, R.; Darby, I.; Becker, G. Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol. Dial. Transplant. 2004, 19, 544-552.
145. Chow, B.S.; Chew, E.G.; Zhao, C.; Bathgate, R.A.; Hewitson, T.D.; Samuel, C.S. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: The additional involvement of iNOS. PLoS One 2012, 7, e42714.
146. Chow, B.S.; Kocan, M.; Bosnyak, S.; Sarwar, M.; Wigg, B.; Jones, E.S.; Widdop, R.E.; Summers, R.J.; Bathgate, R.A.; Hewitson, T.D.; et al. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis. Kidney Int. 2014, 86, 75-85.
147. Huang, X.; Gai, Y.; Yang, N.; Lu, B.; Samuel, C.S.; Thannickal, V.J.; Zhou, Y. Relaxin regulates myofibroblast contractility and protects against lung fibrosis. Am. J. Pathol. 2011, 179, 2751-2765.
148. Yoshida, T.; Kumagai, H.; Suzuki, A.; Kobayashi, N.; Ohkawa, S.; Odamaki, M.; Kohsaka, T.; Yamamoto, T.; Ikegaya, N. Relaxin ameliorates salt-sensitive hypertension and renal fibrosis. Nephrol. Dial. Transplant. 2012, 27, 2190-2197.
149. Hewitson, T.D.; Mookerjee, I.; Masterson, R.; Zhao, C.; Tregear, G.W.; Becker, G.J.; Samuel, C.S. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis. Endocrinology 2007, 148, 660-669.
150. Hewitson, T.D.; Zhao, C.; Wigg, B.; Lee, S.W.; Simpson, E.R.; Boon, W.C.; Samuel, C.S. Relaxin and castration in male mice protect from, but testosterone exacerbates, age-related cardiac and renal fibrosis, whereas estrogens are an independent determinant of organ size. Endocrinology 2012, 153, 188-199.
151. Samuel, C.S.; Zhao, C.; Bond, C.P.; Hewitson, T.D.; Amento, E.P.; Summers, R.J. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis. Kidney Int. 2004, 65, 2054-2064.
152. Danielson, L.A.; Welford, A.; Harris, A. Relaxin improves renal function and histology in aging Munich Wistar rats. J. Am. Soc. Nephrol. 2006, 17, 1325-1333.
153. McDonald, G.A.; Sarkar, P.; Rennke, H.; Unemori, E.; Kalluri, R.; Sukhatme, V.P. Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo. Am. J. Physiol. Renal Physiol. 2003, 285, F59-F67.
154. Sasser, J.M.; Molnar, M.; Baylis, C. Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not Nω-nitro-L-arginine methyl ester hypertensive rats. Hypertension 2011, 58, 197-204.
155. Garber, S.L.; Mirochnik, Y.; Brecklin, C.S.; Unemori, E.N.; Singh, A.K.; Slobodskoy, L.; Grove, B.H.; Arruda, J.A.; Dunea, G. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int. 2001, 59, 876-882.
156. Garber, S.L.; Mirochnik, Y.; Brecklin, C.; Slobodskoy, L.; Arruda, J.A.; Dunea, G. Effect of relaxin in two models of renal mass reduction. Am. J. Nephrol. 2003, 23, 8-12.
157. Lekgabe, E.D.; Kiriazis, H.; Zhao, C.; Xu, Q.; Moore, X.L.; Su, Y.; Bathgate, R.A.; Du, X.J.; Samuel, C.S. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 2005, 46, 412-418.
158. Haase, N.; Rugor, J.; Przybyl, L.; Qadri, F.; Muller, D.N.; Dechend, R. Relaxin does not improve angiotensin II-induced target-organ damage. PLoS One 2014, 9, e93743.
159. Wong, S.E.; Samuel, C.S.; Kelly, D.J.; Zhang, Y.; Becker, G.J.; Hewitson, T.D The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes. Protein Pept. Lett. 2013, 20, 1029-1038.
160. Pini, A.; Shemesh, R.; Samuel, C.S.; Bathgate, R.A.; Zauberman, A.; Hermesh, C.; Wool, A.; Bani, D.; Rotman, G. Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity. J. Pharmacol. Exp. Ther. 2010, 335, 589-599.
161. Sager, G. Cyclic GMP transporters. Neurochem. Int. 2004, 45, 865-873.
162. Jin, X.; Zhang, Y.; Li, X.; Zhang, J.; Xu, D. C-type natriuretic peptide ameliorates ischemia/reperfusion-induced acute kidney injury by inhibiting apoptosis and oxidative stress in rats. Life Sci. 2014, 117, 40-45.
163. Li, P.; Oparil, S.; Novak, L.; Cao, X.; Shi, W.; Lucas, J.; Chen, Y.F. ANP signaling inhibits TGFβ-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells. J. Appl. Physiol. 2007, 102, 390-398.
164. Li, P.; Wang, D.; Lucas, J.; Oparil, S.; Xing, D.; Cao, X.; Novak, L.; Renfrow, M.B.; Chen, Y.F. Atrial natriuretic peptide inhibits transforming growth factor β-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ. Res. 2008, 102, 185-192.
165. Das, S.; Au, E.; Krazit, S.T.; Pandey, K.N. Targeted disruption of guanylyl cyclase-A/natriuretic peptide receptor-A gene provokes renal fibrosis and remodeling in null mutant mice: Role of proinflammatory cytokines. Endocrinology 2010, 151, 5841-5850.
166. Kumar, P.; Periyasamy, R.; Das, S.; Neerukonda, S.; Mani, I.; Pandey, K.N. All-trans retinoic acid and sodium butyrate enhance natriuretic peptide receptor a gene transcription: Role of histone modification. Mol. Pharmacol. 2014, 85, 946-957.
167. Ogawa, Y.; Mukoyama, M.; Yokoi, H.; Kasahara, M.; Mori, K.; Kato, Y.; Kuwabara, T.; Imamaki, H.; Kawanishi, T.; Koga, K.; et al. Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J. Am. Soc. Nephrol. 2012, 23, 1198-1209.
168. Nishikimi, T.; Inaba-Iemura, C.; Ishimura, K.; Tadokoro, K.; Koshikawa, S.; Ishikawa, K.; Akimoto, K.; Hattori, Y.; Kasai, K.; Minamino, N.; et al. Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. Regul. Pept. 2009, 154, 44-53.
169. Makino, H.; Mukoyama, M.; Mori, K.; Suganami, T.; Kasahara, M.; Yahata, K.; Nagae, T.; Yokoi, H.; Sawai, K.; Ogawa, Y.; et al. Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. Diabetologia 2006, 49, 2514-2524.
170. Suganami, T.; Mukoyama, M.; Sugawara, A.; Mori, K.; Nagae, T.; Kasahara, M.; Yahata, K.; Makino, H.; Fujinaga, Y.; Ogawa, Y.; et al. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J. Am. Soc. Nephrol. 2001, 12, 2652-2663.
171. Kasahara, M.; Mukoyama, M.; Sugawara, A.; Makino, H.; Suganami, T.; Ogawa, Y.; Nakagawa, M.; Yahata, K.; Goto, M.; Ishibashi, R.; et al. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J. Am. Soc. Nephrol. 2000, 11, 1691-1701.
172. Ameenuddin, S.; Oehler, E.A.; Burnett J.C.; Chen, H.H. Treatment with CBA-NP a novel chimeric natriuretic peptide attenuates cardiorenal fibrosis and improves diastolic dysfunction in diabetic rat model. J. Card. Fail. 2011, 17, S22.
173. Martin, F.L.; Sangaralingham, S.J.; McKie, P.M.; Huntley, B.K.; Harders, G.E.; Chen, H.H.; Burnett, J.C. Prevention of cardiorenal fibrosis and suppression of proteinuria and aldosterone activation following experimental myocardial infarction with the novel natriuretic peptide CD-NP. J. Card. Fail. 2009, 15, S3.
174. Testani, J.M. Renal subanalysis of the acute study of clinical effectiveness of nesiritide in decompensated heart failure (ASCEND-HF): The end of nesiritide as a cardiorenal therapeutic? Circulation 2014, 130, 936-938.
175. Judge, P.; Haynes, R.; Landray, M.J.; Baigent, C. Neprilysin inhibition in chronic kidney disease. Nephrol. Dial. Transplant. 2014, doi:10.1093/ndt/gfu269.
176. McMurray, J.J.; Packer, M.; Desai, A.S.; Gong, J.; Lefkowitz, M.P.; Rizkala, A.R.; Rouleau, J.L.; Shi, V.C.; Solomon, S.D.; Swedberg, K.; et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014, 371, 993-1004.
177. Martin, P.; Mora, I.; Cortes, M.A.; Calleros, L.; Garcia-Jerez, A.; Ortiz, A.; Rodriguez-Puyol, M.; Rodriguez-Puyol, D.; Olmos, G. Relevant role of PKG in the progression of fibrosis induced by TNF-like weak inducer of apoptosis. Am. J. Physiol. Renal Physiol. 2014, 307, F75-F85.
178. Faria-Costa, G.; Leite-Moreira, A.; Henriques-Coelho, T. Cardiovascular effects of the angiotensin type 2 receptor. Rev. Port. Cardiol. 2014, 33, 439-449.
179. Persson, F.; Lewis, J.B.; Lewis, E.J.; Rossing, P.; Hollenberg, N.K.; Hans-Henrik, P. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: An AVOID substudy. J. Renin Angiotensin Aldosterone Syst. 2012, 13, 118-121.
180. Nadler, J.L.; Hsueh, W.; Horton, R. Therapeutic effect of calcium channel blockade in primary aldosteronism. J. Clin. Endocrinol. Metab. 1985, 60, 896-899.
181. Zhang, J.J.; Bledsoe, G.; Kato, K.; Chao, L.; Chao, J. Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int. 2004, 66, 722-732.
182. Murakami, H.; Yayama, K.; Chao, L.; Chao, J. Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int. 1998, 53, 1305-1313.
183. Xia, C.-F.; Bledsoe, G.; Chao, L.; Chao, J. Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats. Am. J. Physiol. Renal Physiol. 2005, 289, F622-F631.
184. Kumar, P.; Periyasamy, R.; Das, S.; Pandey, K. Retinoic acid and sodium butyrate attenuate renal fibrosis and inflammation in guanylyl cyclase-A/natriuretic peptide receptor-A gene-targeted mice (796.13). FASEB J. 2014, 28, Supplement 796-13.